Logo-npj
Submitted: 17 Jun 2024
Accepted: 07 Sep 2024
ePublished: 02 Oct 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2025;14(1): e12739.
doi: 10.34172/npj.2025.12739
  Abstract View: 114
  PDF Download: 67

Clinical Trial

The effects of oral L-carnitine supplementation on echocardiographic parameters in hemodialysis patients with pulmonary hypertension; a double-blind clinical trial investigation

Afiyeh Mirzaali 1 ORCID logo, Leila Mahmoodnia 2 ORCID logo, Marziyeh Nasiri 3 ORCID logo, Hadi Raeisi Shahraki 4 ORCID logo, Zahra Habibi 3* ORCID logo

1 Department of Internal Medicine, Clinical Research Development Unit, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Department of Internal Medicine, School of Medicine, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 Clinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran
4 Department of Epidemiology and Biostatistics, Faculty of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran
*Corresponding Author: Zahra Habibi, Email: dr_z_habibi@yahoo.com

Abstract

Introduction: Hemodialysis patients face progressive reductions in carnitine levels due to the removal of carnitine during hemodialysis and decreased endogenous synthesis, which may contribute to impaired fatty acid oxidation and endothelial dysfunction, potentially playing a role in the development of pulmonary hypertension.

Objectives: This study sought to assess the impact of oral L-carnitine supplementation on echocardiographic index in hemodialysis patients diagnosed with pulmonary hypertension.

Patients and Methods: This double-blind, placebo-controlled, randomized clinical trial was conducted on hemodialysis patients diagnosed with pulmonary hypertension who were referred to dialysis centers in 2022, in Shahrekord, Iran. Eligible participants were randomly assigned to receive either L-carnitine or placebo for 12 weeks. Informed written consent was taken from all patients and demographic characteristics were collected. Echocardiographic parameters were measured at baseline and after the intervention, including ejection fraction, systolic pulmonary artery pressure (SPAP), mean pulmonary artery pressure (MPAP), and New York Heart Association (NYHA) functional class. Data were collected and compared between control and intervention groups using statistical tests.

Results: The study included 40 participants, divided into control and intervention groups. The mean ages were 65.10 ± 8.66 years for the control group and 56.35 ± 13.76 years for the intervention group. Analysis of echocardiographic parameters revealed significant differences between the groups after three months, with the intervention group showing a notable increase in ejection fraction and significant reductions in NYHA functional class, SPAP, and MPAP compared to the control group.

Conclusion: Our findings showed that L-carnitine positively impacts cardiac function and echocardiographic parameters in hemodialysis patients with pulmonary hypertension. The significant improvements in ejection fraction and reductions in the NYHA functional class, SPAP, and MPAP indicate that L-carnitine may play an effective role in enhancing cardiac performance and improving symptoms in this patient population.

Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20230425057989N1; https://irct.behdasht.gov.ir/trial/69751), and ethical code from Shahrekord University of Medical Sciences (Ethical code#IR.SKUMS.REC.1400.157).


Implication for health policy/practice/research/medical education:

The implications of this study are significant for clinical practice and patient management in hemodialysis patients with pulmonary hypertension. Given the demonstrated positive effects of L-carnitine on cardiac function and hemodynamic parameters, healthcare providers may consider incorporating L-carnitine supplementation as part of a comprehensive treatment strategy to enhance cardiac performance and alleviate symptoms in this vulnerable population. Furthermore, these findings warrant further investigation into the long-term benefits and optimal dosing of L-carnitine, as well as its potential role in broader patient populations with cardiac dysfunction. Ultimately, this research could lead to improved quality of life and clinical outcomes for patients suffering from compromised cardiac function associated with chronic kidney disease and pulmonary hypertension.

Please cite this paper as: Mirzaali A, Mahmoodnia L, Nasiri M, Raeisi Shahraki H, Habibi Z. The effects of oral L-carnitine supplementation on echocardiographic parameters in hemodialysis patients with pulmonary hypertension; a double-blind clinical trial investigation. J Nephropharmacol. 2025;14(1):e12739. DOI: 10.34172/npj.2025.12739.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 115

Your browser does not support the canvas element.


PDF Download: 67

Your browser does not support the canvas element.